[go: up one dir, main page]

SG11201606502YA - Fgf-18 compound dosing regimen - Google Patents

Fgf-18 compound dosing regimen

Info

Publication number
SG11201606502YA
SG11201606502YA SG11201606502YA SG11201606502YA SG11201606502YA SG 11201606502Y A SG11201606502Y A SG 11201606502YA SG 11201606502Y A SG11201606502Y A SG 11201606502YA SG 11201606502Y A SG11201606502Y A SG 11201606502YA SG 11201606502Y A SG11201606502Y A SG 11201606502YA
Authority
SG
Singapore
Prior art keywords
fgf
dosing regimen
compound dosing
compound
regimen
Prior art date
Application number
SG11201606502YA
Inventor
Christoph H Ladel
Hans Guehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201606502YA publication Critical patent/SG11201606502YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201606502YA 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen SG11201606502YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
SG11201606502YA true SG11201606502YA (en) 2016-09-29

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606505UA SG11201606505UA (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
SG11201606502YA SG11201606502YA (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201606505UA SG11201606505UA (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Country Status (25)

Country Link
US (2) US9889179B2 (en)
EP (2) EP3119417B1 (en)
JP (2) JP6431083B2 (en)
KR (2) KR102410988B1 (en)
CN (2) CN106456713A (en)
AR (2) AR099510A1 (en)
AU (2) AU2015220777B2 (en)
BR (2) BR112016018696A2 (en)
CA (2) CA2938791A1 (en)
DK (2) DK3107559T3 (en)
ES (2) ES2688551T3 (en)
HR (2) HRP20181572T1 (en)
HU (1) HUE040350T2 (en)
IL (2) IL247083B (en)
LT (2) LT3119417T (en)
MX (2) MX2016010872A (en)
NZ (2) NZ723139A (en)
PL (2) PL3119417T3 (en)
PT (2) PT3107559T (en)
RS (2) RS57709B1 (en)
RU (2) RU2700582C2 (en)
SG (2) SG11201606505UA (en)
SI (2) SI3107559T1 (en)
WO (2) WO2015124731A1 (en)
ZA (2) ZA201605548B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6510547B2 (en) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Implant containing FGF-18
US9889179B2 (en) 2014-02-20 2018-02-13 Merck Patent Gmbh FGF-18 compound dosing regimen
EP3250925B1 (en) 2015-01-29 2019-04-10 Ares Trading S.A. Immunoassays for highly positively charged proteins
RU2743075C2 (en) 2016-02-22 2021-02-15 Новартис Аг Fxr agonists application methods
CN111163791A (en) 2017-09-29 2020-05-15 默克专利有限公司 Metabolic biomarkers predictive of reactivity to FGF-18 compounds
LT3688468T (en) * 2017-09-29 2022-06-27 Merck Patent Gmbh INFLAMMATORY BIOMARKERS TO PREDICT RESPONSE TO FGF-18
KR20210057764A (en) 2018-09-10 2021-05-21 메르크 파텐트 게엠베하 Markers useful in reinforcement strategies for the treatment of osteoarthritis
JP7671249B2 (en) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Treating Patients at Risk for Rapid Osteoarthritis Progression
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500742C (en) * 2002-10-07 2014-02-18 Zymogenetics, Inc. Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
WO2006014444A1 (en) * 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
WO2007070983A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
UA99818C2 (en) * 2006-08-25 2012-10-10 Эйрэс Трейдинг С.А. Treatment of cartilage disorders
EA015644B1 (en) * 2006-08-25 2011-10-31 Арес Трейдинг С.А. Method of treatment of cartilage disorders
DE102006043260A1 (en) * 2006-09-11 2008-03-27 Krones Ag labeling
CA2830882C (en) * 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
ES2676318T3 (en) 2014-02-20 2018-07-18 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
JP6510547B2 (en) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Implant containing FGF-18
US9889179B2 (en) 2014-02-20 2018-02-13 Merck Patent Gmbh FGF-18 compound dosing regimen

Also Published As

Publication number Publication date
SI3107559T1 (en) 2018-11-30
BR112016018685A2 (en) 2017-10-17
RU2016137292A (en) 2018-03-21
RU2016137292A3 (en) 2018-09-17
ZA201605547B (en) 2019-09-25
AU2015220777B2 (en) 2020-10-22
WO2015124731A1 (en) 2015-08-27
SI3119417T1 (en) 2018-11-30
RS57709B1 (en) 2018-12-31
KR102410986B1 (en) 2022-06-17
DK3107559T3 (en) 2018-10-15
WO2015124727A1 (en) 2015-08-27
RU2016137289A3 (en) 2018-10-19
EP3107559A1 (en) 2016-12-28
ES2689071T3 (en) 2018-11-08
MX2016010872A (en) 2016-11-17
RS57853B1 (en) 2018-12-31
LT3107559T (en) 2018-10-25
US9889179B2 (en) 2018-02-13
NZ723139A (en) 2022-12-23
RU2016137289A (en) 2018-03-21
CN106232622A (en) 2016-12-14
BR112016018696A2 (en) 2017-10-17
PL3107559T3 (en) 2019-01-31
DK3119417T3 (en) 2018-10-22
MX2016010871A (en) 2016-11-17
SG11201606505UA (en) 2016-09-29
PL3119417T3 (en) 2019-01-31
NZ723148A (en) 2022-08-26
CN106456713A (en) 2017-02-22
HRP20181572T1 (en) 2018-11-30
PT3119417T (en) 2018-10-31
ES2688551T3 (en) 2018-11-05
AU2015220777A1 (en) 2016-09-01
KR20160116001A (en) 2016-10-06
ZA201605548B (en) 2018-12-19
CA2938793A1 (en) 2015-08-27
LT3119417T (en) 2018-10-25
HRP20181570T1 (en) 2018-11-30
IL247084A0 (en) 2016-09-29
US20170056474A1 (en) 2017-03-02
KR20160116000A (en) 2016-10-06
CA2938791A1 (en) 2015-08-27
EP3119417A1 (en) 2017-01-25
JP6431083B2 (en) 2018-11-28
AR099558A1 (en) 2016-08-03
RU2700582C2 (en) 2019-09-18
JP6431082B2 (en) 2018-11-28
EP3119417B1 (en) 2018-07-11
AU2015220773A1 (en) 2016-09-01
US9724388B2 (en) 2017-08-08
JP2017512194A (en) 2017-05-18
PT3107559T (en) 2018-10-31
RU2691946C2 (en) 2019-06-19
IL247083B (en) 2019-09-26
EP3107559B1 (en) 2018-07-11
JP2017507142A (en) 2017-03-16
KR102410988B1 (en) 2022-06-17
IL247083A0 (en) 2016-09-29
HUE040350T2 (en) 2019-03-28
AU2015220773B2 (en) 2020-10-08
US20170072017A1 (en) 2017-03-16
AR099510A1 (en) 2016-07-27
IL247084B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
GB2544029B (en) Packages
ZA201800027B (en) Tau-binding antibodies
HUE055109T2 (en) Dosing regimens for anti-tf-antibody drug-conjugates
ZA201605547B (en) Fgf-18 compound dosing regimen
GB2545674B (en) Dosing module
GB201510451D0 (en) Actuated-valve metering
GB201418710D0 (en) Dosage regimen
ZA201800217B (en) Novel dosage regimen tiacumicin compound
GB201516836D0 (en) Dosing regimen of combination
GB201503438D0 (en) Antibodies
IL248782A0 (en) Treatment regimen tiacumicin compound
GB201720519D0 (en) Dosing regimen
GB201718106D0 (en) Dosing regimen
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
GB201609758D0 (en) Dosing Regimen
GB201521216D0 (en) Dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201713609D0 (en) Packages
GB201508437D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201502591D0 (en) Antibodies